AgingResearch.NewsJoin free

ANTI-MIR-34A

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: American Diabetes Association and 3 more
  • Animals1

Outcomes

2

Glucose intolerance

downin mice1

1 study

  1. ANTI-MIR-34A decreases glucose intolerance in mice.

    “antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD(+) levels and alleviated steatosis, inflammation, and glucose intolerance.”

    Animalsin diet-induced obese mice

    Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT

    Aging cell11 Aug 2013

Steatosis

downin mice1

1 study

  1. ANTI-MIR-34A decreases steatosis in mice.

    “antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD(+) levels and alleviated steatosis, inflammation, and glucose intolerance.”

    Animalsin diet-induced obese miceliver

    Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT

    Aging cell11 Aug 2013

More on Steatosis

Latest

Related